Giuseppe Giaccone
机构: Professor of Medicine, Weill Cornell University
每年引用次数
引用次数
引用: 85,795
H-指数: 143
I10-指数 : 624
出版物: 1,224
Prognostic relevance of P-glycoprotein expression in breast cancer
S.C. Linn , G. Giaccone , P.J. van Diest , W.M.D. Blokhuis
Annals of Oncology 6 ( 7) 679 -685
73
1995
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients
A.H. Honkoop , K. Hoekman , Wagstaff J. , E. Boven
Annals of Oncology 7 ( 1) 35 -39
21
1996
A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer An EORTC Lung Cancer Cooperative Group trial
A. Planting , P. Helle , P. Drings , O. Dalesio
Annals of Oncology 7 ( 2) 139 -144
28
1996
Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues
A.-M. C. Dingemans , J. van Ark-Otte , P. van der Valk , R.M. Apolinario
Annals of Oncology 7 ( 6) 625 -630
44
1996
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: A randomized phase II trial of the EORTC lung cancer cooperative group
Ch. Manegold , P. Drings , A. Pawinski , M.-A. Lentz
Annals of Oncology 7 ( 6) 637 -639
10
1996
1115 POSTER Epidermal Ggrowth Factor Receptor Inhibitor (EGFRI)-associated rash: a suggested novel management paradigm. A consensus position from the EGFRI Dermatologic Toxicity Forum
G. Giaccone , B. Melosky , M. Reck
Ejc Supplements 5 ( 4) 146
1
2007
176 POSTER Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors
P. Schöffski , V. Grünwald , G. Giaccone , R. Salazar
Ejc Supplements 6 ( 12) 56
1
2008
Phase II study of ACNU as second-line treatment in small-cell lung cancer
A. S. Th. Planting , T. A. W. Splinter , A. Ardizzoni , J. Estap�
Cancer Chemotherapy and Pharmacology 29 ( 5) 409 -411
7
1992
Analysis of deoxycytidine accumulation in gemcitabine treated patients.
R. Honeywell , C. J. van Groeningen , A. C. Laan , E. Strocchi
Nucleosides, Nucleotides & Nucleic Acids 25 1225 -1232
5
2006
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
R.S. Herbst , F. de Marinis , G. Giaccone , N. Reinmuth
Annals of Oncology 30
13
2019
p53 and chemosensitivity
C.G. Ferreira , C. Tolis , G. Giaccone
Annals of Oncology 10 ( 9) 1011 -1021
158
1999
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients
A. Baars , A.M.E. Claessen , A.J.M. van den Eertwegh , H.E. Gall
Annals of Oncology 11 ( 8) 965 -970
63
2000
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: Single-centre experience in 145 patients
J.M.G.H. van Riel , C.J. van Groeningen , S.H.M. Albers , M. Cazemier
Annals of Oncology 11 ( 12) 1563 -1570
20
2000
A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors.
L. E. Broker , F. Y. De Vos , H. Gall , J. A. Gietema
Journal of Clinical Oncology 22 ( 14) 2029 -2029
7
2004
Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study)
G. Giaccone , C. Debruyne , E. Felip , M. Millward
Journal of Clinical Oncology 22 7020 -7020
19
2004
Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): An EORTC phase II trial (08984)
C. Manegold , B. Biesma , H. Smit , J. Van Meerbeeck
Journal of Clinical Oncology 22 7166 -7166
8
2004
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
A. Thomas , A. Rajan , A. Lopez-Chavez , Y. Wang
Annals of Oncology 24 ( 3) 577 -585
54
2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
S. Ramalingam , J. Crawford , A. Chang , C. Manegold
Annals of Oncology 24 ( 11) 2875 -2880
35
2013
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
R.J. Kelly , A. Thomas , A. Rajan , G. Chun
Annals of Oncology 24 ( 10) 2601 -2606
90
2013
Current chemotherapeutic possibilities in pancreaticobiliary cancer
J.M.G.H. van Riel , C.J. van Groeningen , H.M. Pinedo , G. Giaccone
Annals of Oncology 10 157 -161
29
1999